IP Library Patent Application 18683520
Patent Application
App. No. 18/683,520

PREPARATION OF P2X3 ANTAGONIST

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/683,520
Abstract

Described herein is the preparation of a P2X3 antagonist and chemical intermediates used in the synthetic process.

Claims (86)

1 . A process for the preparation of (S)-4-(3-(4-(tert-butoxycarbonyl)morpholin-2-yl)propanoyl)-3,5-difluorobenzoic acid (Compound 1A):

comprising contacting a compound with the structure:

with a base in a solvent.

2 . The process of claim 1 , wherein the base is aqueous sodium hydroxide.

3 . The process of claim 1 , wherein the solvent is selected from tetrahydrofuran, N-methyl-2-pyrrolidone, methanol, isopropanol, and tert-butanol.

4 . The process of claim 1 , wherein the solvent is isopropanol.

5 . The process of claim 1 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with lithium chloride and acetic acid.

6 . The process of claim 1 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with a compound with the structure:

and a base, in the presence of a solvent.

7 . The process of claim 6 , wherein the base is selected from sodium hydride, lithium bis(trimethylsilyl)amide, potassium tert-butoxide, and triethylamine/magnesium chloride.

8 . The process of claim 6 , wherein the base is triethylamine/magnesium chloride.

9 . The process of claim 6 , wherein the solvent is tetrahydrofuran or 2-methyltetrahydrofuran.

10 . The process of claim 6 , wherein the solvent is 2-methyltetrahydrofuran.

11 . The process of claim 1 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with dimethyl malonate, potassium iodide, and a base.

12 . The process of claim 11 , wherein the base is selected from sodium hydride, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, potassium carbonate, sodium carbonate, and cesium carbonate.

13 . The process of claim 12 , wherein the base is cesium carbonate.

14 . The process of claim 1 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with lithium chloride and acetic acid.

15 . The process of claim 14 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with a compound with the structure:

and a base, in the presence of a solvent.

16 . The process of claim 15 , wherein the base is selected from sodium hydride, lithium bis(trimethylsilyl)amide, potassium tert-butoxide, and triethylamine/magnesium chloride.

17 . The process of claim 15 , wherein the base is triethylamine/magnesium chloride.

18 . The process of claim 15 , wherein the solvent is tetrahydrofuran or 2-methyltetrahydrofuran.

19 . The process of claim 15 , wherein the solvent is 2-methyltetrahydrofuran.

20 . The process of claim 15 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with dimethyl malonate, potassium iodide, and a base.

21 . The process of claim 20 , wherein the base is selected from sodium hydride, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, potassium carbonate, sodium carbonate, and cesium carbonate.

22 . The process of claim 21 , wherein the base is cesium carbonate.

23 . The process of claim 1 , wherein the compound with the structure:

is prepared by a process comprising contacting a compound with the structure:

with toluenesulfonyl chloride and a base in the presence of a solvent.

24 . The process of claim 23 , wherein the base is triethylamine.

25 . The process of claim 23 , wherein the solvent is dichloromethane.

26 . A process for the preparation of (S)-4-(3-(4-(tert-butoxycarbonyl)morpholin-2-yl)propanoyl)-3,5-difluorobenzoic acid (Compound 1A), comprising:

A) the reaction of a compound with the structure:

with toluenesulfonyl chloride and triethylamine to produce a compound with the structure:

B) followed by the reaction of the compound with the structure:

with dimethyl malonate, potassium iodide, and cesium carbonate to produce a compound with the structure:

C) followed by the reaction of the compounds with the structures:

with triethylamine/magnesium chloride to produce a compound with the structure:

D) followed by the reaction of the compound with the structure:

with lithium chloride and acetic acid to produce a compound with the structure;

E) followed by the reaction of the compound with the structure:

with aqueous sodium hydroxide to produce a compound with the structure:

27 . A process for the preparation of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (Compound 1), comprising:

A) the reaction of a compound with the structure:

with toluenesulfonyl chloride and triethylamine to produce a compound with the structure:

B) followed by the reaction of the compound with the structure:

with dimethyl malonate, potassium iodide, and cesium carbonate to produce a compound with the structure:

C) followed by the reaction of the compounds with the structures:

with triethylamine/magnesium chloride to produce a compound with the structure:

D) followed by the reaction of the compound with the structure:

with lithium chloride and acetic acid to produce a compound with the structure;

E) followed by the reaction of the compound with the structure:

with aqueous sodium hydroxide to produce a compound with the structure:

F) followed by the reaction of the compound with the structure:

with hydrogen chloride in ethyl acetate to produce a compound with the structure;

G) followed by the reaction of the compound with the structure:

with methyl chloroformate and sodium bicarbonate to produce a compound with the structure:

H) followed by the reaction of the compound with the structure:

with N-bromosuccinimide and acid to produce a compound with the structure:

I) followed by the reaction of the compound with the structure:

with 2-amino-4-methylpyridine and optionally sodium borohydride to produce a compound with the structure:

J) followed by the reaction of the compound with the structure:

with carbonyldiimidazole and methylamine or methylamine hydrochloride to produce a compound with the structure:

28 . A compound having the structure:

or a co-crystal thereof.

29 . A compound having the structure:

or a co-crystal thereof.

30 . A compound having the structure:

or a co-crystal thereof.

31 . A compound having the structure:

or a co-crystal thereof.

32 . A compound having the structure:

or a co-crystal thereof.

33 . A compound having the structure:

Assignments (6)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
Reel/Frame 071351/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: VILLENEUVE, KARINE; KRONENTHAL, DAVID
To: BELLUS HEALTH COUGH INC.
Reel/Frame 066458/0587 →
MERGER Recorded Feb 14, 2024
From: BELLUS HEALTH COUGH INC.
To: BELLUS HEALTH INC.
Reel/Frame 066596/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: BELLUS HEALTH INC.
To: 14245563 CANADA INC.
Reel/Frame 066596/0934 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: 14245563 CANADA INC.
To: ID BIOMEDICAL CORPORATION OF QUEBEC
Reel/Frame 066597/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: ID BIOMEDICAL CORPORATION OF QUEBEC
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
Reel/Frame 066597/0394 →